Last €0.76 EUR
Change Today +0.017 / 2.30%
Volume 138.5K
PRL On Other Exchanges
Symbol
Exchange
BrsaItaliana
As of 7:10 AM 08/27/14 All times are local (Market data is delayed by at least 15 minutes).

pierrel spa (PRL) Snapshot

Open
€0.73
Previous Close
€0.74
Day High
€0.76
Day Low
€0.73
52 Week High
04/8/14 - €0.85
52 Week Low
11/15/13 - €0.49
Market Cap
37.3M
Average Volume 10 Days
47.1K
EPS TTM
€-0.53
Shares Outstanding
49.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for PIERREL SPA (PRL)

Related News

No related news articles were found.

pierrel spa (PRL) Related Businessweek News

No Related Businessweek News Found

pierrel spa (PRL) Details

Pierrel S.p.A. provides contract research and manufacturing services to the pharmaceutical and life science industries. The company is involved in the development of various types of drugs, such as tube vials, bottles, ampoules, drops, sprays, syrups, gels, creams, ointments, and tablets; and production of active ingredients, including active substances and pharmaceutical formulations. It also provides consulting and operational services for the research and development of new molecules and drug products; and consulting services for clinical and regulatory development programs, as well as operational services for the execution of international phase I-IV, late phase, and non-interventional clinical trials. Pierrel S.p.A. has an agreement with Tixupharma for the development and sale of a device to treat periodontitis patients. The company operates in the United States, Australia, Canada, Russia, and the Middle East. Pierrel S.p.A. is based in Capua, Italy.

pierrel spa (PRL) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: €82.9K
Compensation as of Fiscal Year 2012.

pierrel spa (PRL) Key Developments

Pierrel, Tixupharma to Develop Device to Treat Periodontitis Patients

Pierrel SpA has launched a project to develop jointly with Tixupharma a dentistry medical device to help patients suffering from periodontitis. Pierrel, via its unit Pierrel Pharma Srl, aims to use the device to restore and regenerate the gingival mucous in periodontitis patients, thus avoiding surgery. Pierrel Pharma will invest in tranches in the research programme, with each tranche subject to reaching specific milestones, which include a clinical study supervised by the University of Milan. Pierrel Pharma will also obtain the patents for all dentistry applications in various countries around the world.

Pierrel SpA Announces Sales Results for the Month of May 2014

Pierrel SpA announced sales results for the month of May 2014. For the month, the company’s sales rose 15%.

Pierrel SpA and Smile Biotech Srl Team Up to Develop Dental Cavity Diagnostic Kit

Italian pharmaceutical company Pierrel SpA has launched a project with Smile Biotech Srl to research, develop and sell a kit to diagnose dental caries by measuring the levels of the soluble form of the sCD14 protein in the saliva.Â.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PRL:IM €0.76 EUR +0.017

PRL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for PRL.
View Industry Companies
 

Industry Analysis

PRL

Industry Average

Valuation PRL Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PIERREL SPA, please visit www.pierrel.it. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.